EBV-Specific Transfer Factor in the Treatment Of African Burkitt’s Lymphoma: A Pilot Study

  • F. K. Nkrumah
  • G. Pizza
  • D. Viza
  • J. Neequaye
  • C. De Vinci
  • P. H. Levine
Part of the Developments in Medical Virology book series (DIMV, volume 1)

Summary

Eleven African patients with Burkitt’s lymphoma entered a study to evaluate the efficacy of a transfer factor with specific activity against Epstein-Barr virus. The disease-free interval in the group of treated patients was significantly longer than in the control group. The absence of toxicity and the potential efficacy of the transfer factor indicates the need for more extensive clinical trials in African Burkitt’s lymphoma.

Keywords

Migration Toxicity Hepatitis Lymphoma Transportation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kirsh, M.M., et al. Transfer factor in the treatment of carcinoma of the lung. Ann. Thorac. Surg., 38, 140–145 (1984).PubMedCrossRefGoogle Scholar
  2. Levine, P.H., Nkrumah,. F.K., Ablashi, D.V., Pearson, G.R., Faggioni, A., Viza, D., Lvovsky, E., De Vinci., C., Arid Pizza,, G., Clinical and experimental data on the effect of antiviral agents against oncogenic herpesviruses: Implications for the treatment of nasopharyngeal carcinoma. In: U. Prasad, D.V. Ablashi, P.H. Levine, and G.R. Pearson (eds.),Nasopharyngeal Carcinoma: Current Concepts., pp. 415–422, University of Malaya Press, Kuala Lumpur (1983).Google Scholar
  3. Levine, P.H., Pizza, G., Cannon G., Ablashi, D.V., Armstrong, G., And Viza, D., Cell-mediated immunity to Epstein-Barr virus associated membrane antigens in patients with nasopharyngeal carcinoma. In: A. Grundmann, G. Krueger, and D.V. Ablashi (eds.), Nasopharyngeal Carcinoma: Basic Research as Applied to Diagnosis and Therapy, pp. 137–144, Gustav Fischer Verlag, Stuttgart (1981).Google Scholar
  4. Pizza, G., Viza, D., Ablashi,. D.V., Jerome, L., Armstrong, G., And Levine, P.H., The possible use of specific transfer factor in the treatment of patients with nasopharyngeal carcinoma. In: A. Grundmann, G. Krueger, and D.V. Ablashi (eds.), Nasopharyngeal Carcinoma: Basic Research as Applied to Diagnosis and Therapy pp. 301–308, Gustav Fischer Verlag, Stuttgart (1981).Google Scholar
  5. Pizza, G., Vizay D., Roda, A., Aldini, R., Roda, E., And Barbara, In vitro produced transfer factor for the treatment of chronic active hepatitis. N. Engl. J. Med,, 300, 1332 (1979).PubMedGoogle Scholar
  6. Rosenfeld, F., Vizat D., Phillips, J.T Vich, J.M., Binet, O., and Aron-Brunetiere, R., Traitement des infections herpetiques par le facteur de transfert.Presse Med., 13, 537–539 (1984).PubMedGoogle Scholar
  7. Viza, D., Boucheix, C., Cesarine, J.P., Ablashi, D.V., Armstrong, G.,. Levine, P.H., And Pizza, G., Characterization of human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Biol. Cell, 8t 1721–1726 (1982).Google Scholar
  8. Viza, D., Rosenfeld, F., And Phillips, J., Specific bovine transfer factor for the treatment of herpes infections. In: C.H. Kirkpatrick (ed.), Immunobiology of Transfer Factor, pp. 245–259, Academic Press, New York (1983).Google Scholar
  9. Viza, D., Vich, J.M, Phillips, J., And Rosenfeld, F., Orally administered specific transfer factor for the treatment of herpes infections. Lymphok. Res., 4, 27–30 (1984).Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • F. K. Nkrumah
    • 1
  • G. Pizza
    • 2
  • D. Viza
    • 3
  • J. Neequaye
    • 1
  • C. De Vinci
    • 2
  • P. H. Levine
    • 4
  1. 1.Burkitt Tumor ProjectUniv. of Ghana Medical SchoolAccraGhana
  2. 2.Ospedale Marcello MalpighiBolognaItaly
  3. 3.Faculte de Medecine BroussaisParisFrance
  4. 4.National Cancer InstituteBethesdaUSA

Personalised recommendations